diabetes%20insipidus
DIABETES INSIPIDUS
Diabetes insipidus is a polyuric disease characterized by excretion of a large volume of hypotonic urine and hypernatremia. It is due to the absence of antidiuretic hormone.
Central (hypothalamic or neurohypophyseal) diabetes insipidus is the inability to secrete & produce vasopressin in the neurohypophyseal system. It is due to damage to the pituitary gland & hypothalamus, may be due to diseases, head injuries, neurosurgery, infection or genetic or autoimmune disorders.
In nephrogenic diabetes insipidus, there is inappropriate renal response to vasopressin. Kidney function may be impaired by drugs & by chronic disorders like polycystic kidney disease, sickle cell disease, kidney failure, partial ureteral block, hypokalemia, hypocalcemia, low protein diet & genetic disorders.
Primary polydipsia have abnormal increase in fluid intake.

Diabetes%20insipidus Treatment

Pharmacotherapy

Central DI

Desmopressin

  • 1st-line pharmacotherapy agent
  • Oral, intranasal & parenteral forms are available
  • Actions: Analogue of naturally occurring vasopressin
    • Antidiuretic effect is greater & more prolonged than vasopressin
    • Urine volume is decreased & osmolality is increased
    • Less vasopressor activity than vasopressin

Chlorpropamide

  • Use is limited to patients who have partial central DI
    • Patient still secretes vasopressin but in insufficient quantity
  • Actions: May work by increasing sensitivity of renal tubules to circulating endogenous vasopressin
  • Effects: May achieve 25-75% reduction in polyuria
  • Side effects & limited antidiuretic effect limit their use

Thiazide & Related Diuretics

  • Actions: May work by reducing extracellular Na & decreasing glomerular filtration
  • Effects: May achieve 25-50% reduction in polyuria
  • Side effects & limited antidiuretic effect limit their use
  • Use should be combined w/ low osmolar & low Na diet

Carbamazepine

  • Actions: May enhance the response to antidiuretic hormone
  • Can lower urine output by as much as 50-60%

Clofibrate

  • Actions: May increase the release of antidiuretic hormone

Nephrogenic DI

Thiazide & Related Diuretics

  • Use should be combined w/ low osmolar & low Na diet
  • Actions: Increase Na loss at the cortical diluting tubule by inhibiting Na reabsorption
  • Effects: Can usually obtain 50% reduction in polyuria
  • May combine w/ K-sparing diuretic if hypokalemia occurs

Potassium-Sparing Diuretics

  • No untoward effects reported when combined w/ thiazide diuretics to correct hypokalemia
  • Actions: Act on the distal renal tubules, cause an increase in the excretion of Na & reduce the secretion of K

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

  • Indomethacin, Tolmetin & Ibuprofen
  • May have an additive effect w/ thiazide diuretics in reducing water excretion in some patients
  • Actions: Prostaglandin synthetase inhibitors which reduce urine flow

Non-Pharmacological Therapy

Central DI

  • Small children w/ DI may have rapid changes in osmolality
  • Family needs to be educated to gauge appropriate fluid intake & urine output
    • Daily wt may be used as index of fluid balance
    • Regular measurement of electrolytes may be required especially during beginning stages of treatment
  • Appetite, linear growth & temperature should be monitored during all clinic visits
    • A low sodium and low protein diet is recommended

Familial

  • Genetic counseling & follow-up

Nephrogenic DI

Drug-Induced

  • Discontinue offending agent
    • May take a few wk to see improvement

Familial

  • Low sodium & low osmolar diet
  • Infants: Human milk is preferred because of protein content (6%)
    • Decrease Na intake to 0.7 mEq/kg/day
  • Children: 8% of total daily calories should be from protein
    • Na intake should be <0.7 mEq/kg/day
  • Genetic counseling & follow-up
  • Appetite, linear growth & temperature should be monitored during all clinic visits
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, Yesterday

The addition of methylprednisolone to standard care* reduced mortality risk in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), according to a study from China.

05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.